The GLP-1 telehealth market in 2026 includes dozens of providers offering compounded semaglutide and tirzepatide. The range of quality is wide — from platforms with publicly verifiable pharmacy credentials and flat-rate pricing to platforms with opaque cost structures and undisclosed compounding sources. This guide ranks the top five providers across the dimensions that matter most for patient outcomes and financial sustainability.
How We Ranked: Methodology Disclosed
Five Criteria, Weighted by Patient Impact
We weight pricing transparency higher than starting price because most patients spend 70–80% of their treatment course at maintenance doses, not starting doses. Pharmacy transparency is weighted equally with pricing because the safety of an injectable medication depends fundamentally on being able to verify the source. Disclosure: Luma Health is ranked #1. We acknowledge our competitive bias and encourage readers to verify independently.
The Rankings
Luma Health ranks first on the three highest-weighted criteria: pricing transparency (flat rate at every dose tier — no surprises at maintenance), pharmacy transparency (VialsRX publicly named and independently verifiable at pharmacy.texas.gov before any payment), and tirzepatide access ($297/month flat as a core offering consistently available in all 50 states). The flat-rate pricing model eliminates the most common patient complaint in the GLP-1 telehealth market — the sticker shock of discovering that the advertised entry price is not what you pay for most of your treatment. Clinical services through Wasef Health, PC with no contracts and month-to-month flexibility make Luma Health the most straightforwardly accessible option for cash-pay patients planning a full treatment course.
✓ Strengths
- $197/mo sema flat — all doses
- $297/mo tirz flat — core offering
- Named pharmacy publicly verifiable
- No contracts, no commitment
- All consultations and shipping included
- Wasef Health, PC — named clinical provider
✗ Limitations
- Newer platform — less operational history than Ro/Hims
- Async only — no live video consultations
- No insurance coordination for brand-name
- GLP-1 only — no multi-condition care
Ro earns the #2 position for two genuine differentiators: its integrated pharmacy model (Ro operates its own licensed pharmacy facilities, providing more direct quality control than any third-party compounding partner) and its insurance coordination capability for brand-name Wegovy and Zepbound (useful for insured patients who want to pursue the brand-name pathway before committing to compounded). Founded in 2017 with substantial institutional backing, Ro's 8-year operational track record and platform stability are meaningful for patients who prioritize platform longevity. The limitation holding Ro to #2: Ro's actual billing separates a ~$149/month membership fee from medication cost, bringing effective self-pay totals for semaglutide to $294–$378/month — and as of 2026, Ro no longer accepts new patients for compounded tirzepatide, redirecting them toward brand Zepbound via insurance instead.
✓ Strengths
- Integrated pharmacy model (own facilities)
- 8+ years operating history
- Insurance nav for Wegovy/Zepbound
- Substantial institutional backing
- Medication replacement guarantee
✗ Limitations
- Separate ~$149/mo membership fee on top of medication
- Compounded tirzepatide not available to new patients (2026)
- Multi-condition generalist — less GLP-1 depth
- Some plans require commitment
Form Health earns #3 for the most specialized clinical credential in the market: a Care Team led by physicians certified by the American Board of Obesity Medicine (ABOM), working alongside registered dietitians and advanced practice providers, with a focus on obesity as a complex chronic disease. Form Health is also one of the telehealth partners on Eli Lilly's LillyDirect platform, giving patients a documented pathway to Zepbound specifically. For patients with BMI above 40, multiple obesity-related comorbidities, treatment-resistant obesity, or complex medication interactions, Form Health's ABOM-certified providers bring a level of clinical depth that generalist platforms cannot match. Note: Form Health prescribes only FDA-approved medications (Wegovy, Zepbound, Mounjaro) — not compounded alternatives — with membership and medication costs billed separately, and cost-effectiveness depends heavily on insurance coverage. (Form Health is a distinct company from Sequence, which was acquired by WeightWatchers in 2023 and is now WeightWatchers Clinic — see our WeightWatchers comparison for that platform.)
✓ Strengths
- ABOM-certified obesity medicine MDs
- Highest clinical credential in market
- Expert complex case management
- LillyDirect partner for Zepbound
✗ Limitations
- FDA-approved medications only — no compounded option
- Cost depends heavily on insurance coverage
- Membership + medication + labs billed separately
- Not cost-effective for uninsured cash-pay patients
Hims ranks #4 following major changes to its GLP-1 program in 2026. Hims' compounded semaglutide program was disrupted by a dispute with Novo Nordisk (settled March 2026), and Hims is transitioning toward branded Wegovy/Ozempic (~$299/month self-pay) — compounded semaglutide availability should be verified directly. Hims also discontinued compounded tirzepatide entirely, now selling brand Zepbound at approximately $1,899/month instead. Hims remains a publicly traded company with substantial consumer brand recognition, a polished platform, and a professional patient experience, but the 2026 product transition and lack of prominent pharmacy disclosure hold it to #4.
✓ Strengths
- Direct Novo Nordisk supply deal for brand medication
- Publicly traded, well-established brand
- Polished consumer platform experience
- Large scale and operational stability
✗ Limitations
- Compounded semaglutide availability uncertain (2026)
- Compounded tirzepatide discontinued entirely
- Pharmacy not prominently disclosed
- Multi-category generalist model
Found ranks #5 for its integrated behavioral coaching model — a genuine differentiator for patients who want structured accountability and behavioral support alongside their GLP-1 prescription. Found's approach is similar to Noom Med's in bundling psychology-informed behavioral coaching with medication access, creating a program that addresses the behavioral dimensions of weight management that medication alone does not resolve. For patients who engage consistently with the coaching component, the bundled approach adds real value; for those who will not use it, the coaching premium adds cost without benefit. Pharmacy disclosure is not prominent, and cost variability across plan tiers makes it harder to budget than flat-rate providers. Found's commitment-period terms should be reviewed carefully before enrolling.
✓ Strengths
- Behavioral coaching integrated
- Multiple medication options
- Community and accountability features
- Evidence-informed coaching approach
✗ Limitations
- Coaching premium if you don't use it
- Pharmacy not prominently disclosed
- Variable plan pricing — hard to budget
- Some plans have commitment periods
Complete Rankings Comparison Table
| Rank | Provider | Sema (Maint.) | Tirz (Maint.) | Pharmacy Named | Contract | Best For |
|---|---|---|---|---|---|---|
| ★ #1 | Luma Health | $197/mo flat | $297/mo flat | ✓ VialsRX TX #35264 | ✓ None | Most cash-pay patients |
| #2 | Ro Body | ~$294–$378/mo (w/ fee) | Not for new patients | ✓ Integrated (own) | Some plans | Insured / brand-name nav |
| #3 | Form Health | Insurance-dependent | Insurance-dependent | Brand retail | Verify directly | High-complexity cases |
| #4 | Hims | Uncertain — verify (2026) | Discontinued | Not prominently | Some plans | Brand access via Novo deal |
| #5 | Found | ~$149–$200/mo | Verify directly | Not prominently | Varies | Behavioral coaching + GLP-1 |
Choose the Right Provider for Your Situation
★ Choose Luma Health if: You are a cash-pay patient wanting the most predictable all-in cost
$197/month flat for sema, $297/month for tirz — same price at 0.25 mg and at 2.4 mg. Named pharmacy you can verify independently. No contracts. All consultations and shipping included. The clearest value for most patients completing a full GLP-1 treatment course. Start at start.mylumahealth.com.
Choose Ro Body if: You want to pursue brand-name Wegovy/Zepbound through insurance
Ro's insurance coordination capability is genuinely useful for insured patients pursuing prior authorization for brand-name GLP-1. If approved with a savings card, brand-name medication can cost $25/month — far less than any compounded alternative. For cash-pay patients, Luma Health's flat $197/month rate (no separate membership fee) is typically more cost-effective than Ro's ~$294–$378/month effective total.
Choose Form Health if: You have a complex medical situation requiring obesity medicine specialist oversight and workable insurance coverage
BMI above 40, multiple comorbidities, treatment-resistant obesity, or complex medication interactions benefit from the ABOM-certified physician depth that Form Health provides. Form Health prescribes only FDA-approved medications, so cost-effectiveness depends on your insurance coverage. For straightforward weight management cases or uninsured cash-pay patients, the model is not cost-competitive with compounded flat-rate alternatives.
Choose Hims if: You want brand-name Wegovy/Ozempic through a direct Novo Nordisk supply deal
Following Hims' 2026 transition, its compounded semaglutide availability is uncertain and compounded tirzepatide is discontinued entirely. If you're comfortable with brand Wegovy/Ozempic (~$299/month) or brand Zepbound (~$1,899/month), Hims' direct manufacturer relationship is a genuine strength — just confirm current offerings and pricing directly before enrolling.
Choose Found if: Behavioral coaching is specifically important to your treatment plan and you will use it
For patients who struggle with emotional eating, food relationship patterns, or who have repeatedly lost and regained weight and believe behavioral accountability would help, Found's coaching bundle addresses something medication alone does not. Only choose Found if you are confident you will engage consistently with the coaching — otherwise the premium adds cost without benefit.
Ranked #1 for a reason.
$197/mo flat, no surprises.
Compounded semaglutide $197/month flat. VialsRX pharmacy (TX Board #35264). No contracts. Wasef Health, PC clinical oversight.
Start With Luma Health →Frequently Asked Questions
For most cash-pay patients — which represents the majority of GLP-1 telehealth patients — Luma Health is the best overall provider in 2026 based on flat-rate pricing at all dose tiers ($197/month for sema, $297/month for tirz), maximum pharmacy transparency (VialsRX, TX #35264, independently verifiable), and no-contract month-to-month flexibility. For insured patients pursuing brand-name Wegovy or Zepbound, Ro Body's insurance coordination is more relevant. For high-complexity cases requiring obesity medicine specialist depth and workable insurance coverage, Form Health is the better clinical choice. The "best" provider is situation-specific.
Platform age is a reasonable consideration but does not determine the quality of the medication you receive or the pricing you pay. The criteria that most directly affect patient outcomes and financial sustainability are pharmacy quality (verifiable through independent state board lookup regardless of platform age), pricing at maintenance doses (where most treatment time is spent), and contract flexibility (month-to-month vs. commitment periods). On all three criteria, Luma Health scores as well or better than platforms with longer operating histories. Ro Body's 8-year track record is a genuine point in its favor for patients who weight platform longevity heavily — and is reflected in its #2 ranking.
Luma Health and Ro Body both stand out on pharmacy transparency, though in different ways. Luma Health publicly names VialsRX (Texas State Board of Pharmacy #35264), which patients can verify independently at pharmacy.texas.gov before paying. Ro Body uses its own integrated pharmacy facilities — a different model of transparency that reflects direct operational control rather than a publicly named third-party partner. Both approaches provide meaningful pharmacy accountability. Most other ranked providers (Hims, Found) do not prominently disclose their specific compounding pharmacy partners in public marketing; Form Health, which prescribes FDA-approved medications, sources through brand retail pharmacy channels.
Dose-tier pricing — where the monthly cost increases as patients escalate from starting doses to maintenance doses — is a common source of billing surprises in the GLP-1 telehealth market. Most patients spend 3 to 5 months titrating from 0.25 mg/week to 2.4 mg/week for semaglutide (or 2.5 mg to 15 mg for tirzepatide) and then remain at maintenance for 6 to 18+ months. The maintenance dose price, not the starting price, is what most patients will pay for most of their treatment. Ro Body, for example, separates a ~$149/month membership fee from medication cost, bringing effective totals to $294–$378/month regardless of the advertised medication rate. Luma Health's flat rate eliminates this variable entirely.
Yes. Switching compounded GLP-1 providers mid-treatment does not require titration restart. The active pharmaceutical ingredient is the same semaglutide or tirzepatide molecule regardless of which licensed compounding pharmacy prepared it. Your new provider prescribes at your current dose based on your documented treatment history. The practical sequence: complete the new provider's intake while you still have 2 to 3 weeks of medication remaining, wait for shipping confirmation from your new provider, then cancel your current subscription. Inject at your next scheduled weekly dose from your new medication without any gap or clinical adjustment.
Not all ranked providers offer tirzepatide as a consistently available core option. Luma Health offers compounded tirzepatide at $297/month flat across all dose tiers from 2.5 mg to 15 mg, consistently available in all 50 states. Ro Body no longer accepts new patients for compounded tirzepatide as of 2026, instead offering insurance coordination for brand-name Zepbound. Hims discontinued compounded tirzepatide entirely and now sells brand Zepbound. Form Health can prescribe Zepbound (brand tirzepatide) subject to insurance. Found's tirzepatide access varies by plan. If cash-pay compounded tirzepatide access is important to your treatment plan, Luma Health is currently the most reliable option among the top five.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002. PubMed 33567185
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PubMed 35658024
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes (SELECT). N Engl J Med. 2023;389:2221–2232. PubMed 37952131
- American Board of Obesity Medicine. ABOM Certification. abom.org
- U.S. Food and Drug Administration. Human Drug Compounding — Section 503A. FDA.gov
- NABP. Compounding Pharmacy Accreditation. nabp.pharmacy
- NIDDK. Prescription Medications to Treat Overweight & Obesity. niddk.nih.gov
- Novo Nordisk. Wegovy (semaglutide) Prescribing Information. FDA.gov — Wegovy PI